17-Jul-2026
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
Globe Newswire (Mon, 13-Jul 8:35 PM ET)
Ryoncil Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026
Globe Newswire (Thu, 9-Jul 8:30 PM ET)
Globe Newswire (Tue, 30-Jun 8:38 PM ET)
Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility
Globe Newswire (Wed, 24-Jun 8:59 PM ET)
Globe Newswire (Wed, 29-Apr 8:55 PM ET)
Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain
Globe Newswire (Tue, 28-Apr 8:53 PM ET)
Market Chameleon (Mon, 13-Apr 4:50 AM ET)
Strong Ryoncil® Performance Drives Revenue Gains and Expands Mesoblast's Growth Pipeline
Market Chameleon (Fri, 27-Feb 3:44 AM ET)
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
Mesoblast Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol MESO.
As of July 17, 2026, MESO stock price declined to $17.32 with 393,004 million shares trading.
MESO has a beta of 1.77, meaning it tends to be more sensitive to market movements. MESO has a correlation of 0.11 to the broad based SPY ETF.
MESO has a market cap of $2.24 billion. This is considered a Mid Cap stock.
Last quarter Mesoblast Limited - American Depositary Shares reported $51 million in Revenue and -$.03 earnings per share. This beat revenue expectation by $34 million and exceeded earnings estimates by $.17.
In the last 3 years, MESO traded as high as $22.00 and as low as $1.61.
The top ETF exchange traded funds that MESO belongs to (by Net Assets): IBB, APIE, QQQS, IBBQ, BIB.
MESO has outperformed the market in the last year with a price return of +40.4% while the SPY ETF gained +19.5%. MESO has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +5.2% and +20.4%, respectively, while the SPY returned +4.9% and -0.2%, respectively.
MESO support price is $17.05 and resistance is $18.67 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MESO shares will trade within this expected range on the day.